Antibiotic AY24,668 and process of preparation

Claim 1

Solid AY24,668, an antibiotic which a. gives a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.

Claim 5

A method of inhibiting the growth of pathogenic fungi in a mammal which comprises administering to the mammal an antifungally effective amount of the antibiotic AY24,668 which a. is a solid giving a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.

Claim 6

A method of inhibiting the growth of pathogenic fungi in a mammal which comprises administering to the mammal an antifungally effective amount of the antibiotic AY24,668 which a. is a solid giving a colorless, crystalline compound with a melting point of 122° to 124° C., after recrystallization from diethyl ether; b. is soluble in diethyl ether, chloroform, acetone, methanol and dimethylformamide, very sparingly soluble in hexane and petroleum ether and substantially insoluble in water; c. shows a uniform spot on thin layer plates of silica gel; d. has a characteristic elemental analysis of about C, 67.75%, H, 8.93% N, 1.72%; e. exhibits the following characteristic absorption maxima in its ultraviolet absorption spectrum (95% ethanol): 267 nm (E 1cm 1% 421), 277 nm (E 1cm 1% 549) and 288 nm (E 1cm 1% 423); f. has a characteristic infrared absorption spectrum shown in accompanying FIG. 1; g. has a characteristic nuclear magnetic resonance spectrum as shown in accompanying FIG. 2; h. has a minimum inhibitory concentration of 0.36 to 10.0 μg/ml against Candida albicans; and i. exhibits a LD 50 (i.p., mice) of >900 mg/kg.